H.C. Wainwright reinstated coverage of First Wave BioPharma with a Neutral rating and no price target. The company’s business combination with ImmunogenX completed and latiglutenase may enter Phase 3 trial in celiac disease in the first half of 2025, the analyst tells investors in a research note. The firm sees a substantial market opportunity without approved therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FWBI:
- First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
- First Wave BioPharma announces acceptance of two abstracts on celiac disease
- First Wave BioPharma price target lowered to $36 from $40 at Roth MKM
- First Wave Bio Merges with ImmunogenX, Eyes Celiac Breakthrough
- First Wave BioPharma completes business combination with ImmunogenX